<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03153462</url>
  </required_header>
  <id_info>
    <org_study_id>KTE-C19-109</org_study_id>
    <secondary_id>2015-005007-86</secondary_id>
    <nct_id>NCT03153462</nct_id>
  </id_info>
  <brief_title>Axicabtagene Ciloleucel Expanded Access Study</brief_title>
  <acronym>ZUMA-9</acronym>
  <official_title>A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kite, A Gilead Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <brief_summary>
    <textblock>
      A multicenter, open-label expanded access protocol for the treatment of subjects with&#xD;
      relapsed/refractory large B-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Relapsed/Refractory Diffuse Large B Cell Lymphoma</condition>
  <condition>Relapsed/Refractory Primary Mediastinal B Cell Lymphoma</condition>
  <condition>Relapsed/Refractory Transformed Follicular Lymphoma</condition>
  <condition>Relapsed/Refractory High-Grade B-Cell Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Axicabtagene Ciloleucel</intervention_name>
    <description>Axicabtagene Ciloleucel and A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.</description>
    <other_name>Yescarta®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed large B-cell lymphoma, including the following types:&#xD;
&#xD;
               1. DLBCL, not otherwise specified&#xD;
&#xD;
               2. Primary mediastinal large B-cell lymphoma&#xD;
&#xD;
               3. High-grade B-cell lymphoma&#xD;
&#xD;
               4. DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL)&#xD;
&#xD;
          2. Relapsed or refractory disease, defined as one or more of the following:&#xD;
&#xD;
               1. No response to first-line therapy (primary refractory disease); subjects who are&#xD;
                  intolerant to first-line therapy chemotherapy are excluded OR&#xD;
&#xD;
               2. No response or relapse to second or greater lines of therapy OR&#xD;
&#xD;
               3. Relapsed after ASCT&#xD;
&#xD;
          3. Subjects must have received adequate prior therapy including at a minimum:&#xD;
&#xD;
               1. anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20&#xD;
                  negative, and&#xD;
&#xD;
               2. an anthracycline containing chemotherapy regimen;&#xD;
&#xD;
          4. No evidence, suspicion, and/or history of central nervous system (CNS) involvement of&#xD;
             lymphoma&#xD;
&#xD;
          5. Age 18 or older&#xD;
&#xD;
          6. Eastern cooperative oncology group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          7. Absolute neutrophil count ANC ≥1000/μL&#xD;
&#xD;
          8. Platelet count ≥75,000/μL&#xD;
&#xD;
          9. Absolute lymphocyte count ≥100/μL&#xD;
&#xD;
         10. Adequate renal, hepatic, pulmonary and cardiac function defined as:&#xD;
&#xD;
               1. Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min&#xD;
&#xD;
               2. Serum alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤2.5 upper&#xD;
                  limit of normal (ULN)&#xD;
&#xD;
               3. Total bilirubin ≤1.5 mg/dL, except in subjects with Gilbert's syndrome.&#xD;
&#xD;
               4. Cardiac ejection fraction ≥ 50% and no evidence of pericardial effusion within&#xD;
                  180 days provide the subject did not receive an anthracycline based treatment or&#xD;
                  experience a cardiac event or change in performance status&#xD;
&#xD;
               5. No clinically significant pleural effusion&#xD;
&#xD;
               6. Baseline oxygen saturation &gt;92% on room air&#xD;
&#xD;
         11. Cohort 2 inclusion criteria: Subjects whose commercial manufacture of axicabtagene&#xD;
             ciloleucel did not meet commercial release specification(s)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g.&#xD;
             cervix, bladder, breast) or follicular lymphoma unless disease free for at least 3&#xD;
             years&#xD;
&#xD;
          2. History of allogeneic stem cell transplantation (SCT)&#xD;
&#xD;
          3. Prior CD19 targeted therapy&#xD;
&#xD;
          4. Prior chimeric antigen receptor therapy or other genetically modified T-cell therapy&#xD;
&#xD;
          5. History of severe, immediate hypersensitivity reaction attributed to aminoglycosides&#xD;
&#xD;
          6. Presence or suspicion of fungal, bacterial, viral, or other infection that is&#xD;
             uncontrolled or requiring intravenous (IV) antimicrobials for management. Simple&#xD;
             urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if&#xD;
             responding to active treatment and after consultation with the Kite Pharma Medical&#xD;
             Monitor&#xD;
&#xD;
          7. History of human immunodeficiency virus (HIV) infection or acute or chronic active&#xD;
             hepatitis B or hepatitis C infection. Subjects with a history of hepatitis infection&#xD;
             must have cleared their infection as determined by standard serological and genetic&#xD;
             testing per current Infectious Diseases Society of America (IDSA) guidelines&#xD;
&#xD;
          8. History or presence of primary CNS lymphoma and/or CNS disorder such as seizure&#xD;
             disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any&#xD;
             autoimmune disease with CNS involvement&#xD;
&#xD;
          9. Cohort 2 exclusion criteria: Any medical condition that, deemed by the investigator,&#xD;
             may interfere with assessment of safety or efficacy of study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Kite Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Kite, A Gilead Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital and Clinics</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Hospital Investigational Drug Services</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

